PTEN (Phosphatase and Tensin Homolog) Gene Mutation Analysis
Phosphatase and tensin homolog (PTEN) gene is located at 10q23.31, that encodes enzyme that acts as a tumor suppressor. The protein is found in almost all tissues and its function is executed by inhibiting or negatively regulating PI3K-akt pathway which controls cell growth, proliferation, survival, and metabolism. Therefore, decreased function due to mutations or posttranslational modification is seen in sporadic or inherited cancers syndromes. These include: PTEN hamartoma tumor syndrome and related conditions (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome), Proteus syndrome and Proteus-like syndrome (PLS). Germline PTEN mutations are also associated with increased risk for specific malignancies (breast, thyroid, renal, and endometrial cancers) as well as neurodevelopmental disorders, such as autism and mental retardation.
Cowden syndrome is the most common hamartoma syndrome and is clinically associated with multiple trichilemmomas, mucocutaneous papillomatous papules, and macrocephaly. Affected individuals are at an increased risk for breast, thyroid, and endometrial carcinoma.
Somatic mutations of the PTEN gene are common in human cancers. Mutations have been shown to be associated with primary glioblastomas (20– 40 %), and astrocytomas. Interestingly, they are typically absent in secondary glioblastomas and other gliomas. In glioblastoma, PTEN is often altered by loss of heterozygosity (LOH) at 10q. PTEN mutations and 10q LOH are both negative prognostic factors in patients with high-grade gliomas. LOH analysis or FISH can be used for evaluation. PTEN mutations are also associated with breast, lung, and prostate cancer as well as melanoma and head and neck squamous cell carcinoma.
Lastly, since the function of PTEN protein is directly or indirectly linked to PI3K-akt kinase, testing for PTEN can be used for anti-kinase therapy selection, especially in targeted therapies for the receptor tyrosine kinases pathway (e.g., trastuzumab).
- Diagnosis of hamartoma tumor syndromes (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome and Proteus-like syndrome)
- As an aid in diagnosis of glioblastomas and other gliomas
- Prognostic and predictive marker for therapy treatment and disease management
Negative Results:
- Negative results decrease the likelihood but does not rule out a diagnosis of PTEN Hamartoma Tumor syndrome.
Positive Results:
- Detection of any pathogenic mutation (variants) is consistent with a diagnosis of PTEN Hamartoma Tumor syndromes.
- If mutation(s) identified, genetic testing for family members is recommended.
No reportable variants were identified (Negative for mutation analyzed)
Whole blood (EDTA/lavender top tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unacceptable
- Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562. [PMID: 29858604]
- J Natl Cancer Inst. 1999 Nov 3;91(21):1820-8. [PMID: 10547389]
- Cancer Sci. 2009 Dec;100(12):2235-41. [PMID: 19737147]
- Cold Spring Harb Perspect Med. 2019 Dec 2;9(12). [PMID: 31501265]
- Science. 1997 Mar 28;275(5308):1943-7. [PMID: 9072974]
- PLoS Biol. 2003 Dec;1(3):E59. [PMID: 14691534]